Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab extension in relapsing NMO
NCT02003144Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of eculizumab in neuromyelitis optica (NMO), sponsored by Alexion Pharmaceuticals. Started Jan 2015; status: completed.
02
Drugs
eculizumab
03
Conditions
neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT02003144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02003144.